Yale School of Medicine

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials (2025) Lee MM, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, Mann JF, et al. Journal article Author Correction: Matrix-producing neutrophils populate and shield the skin (Nature, (2025), 10.1038/s41586-025-08741-5) (2025) Vicanolo T, Özcan A, Li JLY, Huerta-López C, Ballesteros I, Rubio-Ponce A, Dumitru AC, et al. Journal article, Erratum Upregulation versus loss of function of NTRK2 in 44 affected individuals leads to 2 distinct neurodevelopmental disorders (2025) Berger E, Jauss RT, Ranells JD, Zonic E, von Wintzingerode L, Wilson A, Wagner J, et al. Journal article Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor (2024) Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro AB, Rubenbauer L, Rao VS, Burlein S, et al. Journal article Multimodal assessment of brain stiffness variation in healthy subjects using magnetic resonance elastography and ultrasound time-harmonic elastography (2024) Klemmer Chandía S, Schattenfroh J, Brinker ST, Tzschaetzsch H, Sack I, Meyer T Journal article Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy (2024) Gudera JA, Baehring JM, Karschnia P Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article EANS Epilepsy surgery Brain Dissection Course Vienna 2024 (2024) Rössler K, Van Roost D, Schijns O, Ackermans L, Delev D, Batista PD, Erőss L, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article